The fund itself, which began with £300M, is now pegged at £600M. Oxford University spinout Vaccitech raised $27m ( £20m ) through series A funding from GV and Sequoia China , along with existing investor Oxford University and Oxford University . The funds will enable Sequoia China to expand its business, develop its lab structure and push its products, including a universal influenza vaccine and a prostate cancer therapeutic in development. Vaccitech CEO, Tom Evans , said that the company is much faster at bringing its products to the market than most, because it is in phase II of clinical trials for the flu and prostate cancer vaccines.
Oxford University spinout Vaccitech raised $27m ( £20m ) through series A funding from GV and Sequoia China , along with existing investor Oxford University and Oxford University . The funds will enable Sequoia China to expand its business, develop its lab structure and push its products, including a universal influenza vaccine and a prostate cancer therapeutic in development. Vaccitech CEO, Tom Evans , said that the company is much faster at bringing its products to the market than most, because it is in phase II of clinical trials for the flu and prostate cancer vaccines.